648 results on '"Friberg, Lena E."'
Search Results
102. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression
103. Characterizing variability in warfarin dose requirements in children using modelling and simulation
104. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing
105. Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates: Population Modelling of a Prospective Study
106. Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future
107. Pivotal Role of Translation in Anti‐Infective Development
108. Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework: A Quantitative Modeling Framework
109. Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae : interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data
110. Activated Charcoal Decreases the Risk of QT Prolongation After Citalopram Overdose
111. Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients
112. Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose
113. The Population Pharmacokinetics of Citalopram After Deliberate Self-Poisoning: A Bayesian Approach
114. Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
115. Mechanistic Models for Myelosuppression
116. Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats
117. Model-based Dose Individualization of Sunitinib in Gastrointestinal Stromal Tumors
118. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes
119. How preclinical infection models help define antibiotic doses in the clinic
120. Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment
121. Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data
122. Efficacy of Antibiotic Combinations against Multidrug-Resistant Pseudomonas aeruginosa in Automated Time-Lapse Microscopy and Static Time-Kill Experiments
123. Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coli Exposed to Cefuroxime
124. Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
125. Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time
126. Model-Informed Drug Development in Pulmonary Delivery: Semimechanistic Pharmacokinetic–Pharmacodynamic Modeling for Evaluation of Treatments against Chronic Pseudomonas aeruginosa Lung Infections
127. Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin
128. Pharmacometrics and Systems Pharmacology 2030
129. Reply to Wilson et al
130. A Semi-Mechanistic Model of CP-690,550-Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis
131. Erratum to: Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen
132. Model-Based Neutrophil-Guided Dose Adaptation in Chemotherapy: Evaluation of Predicted Outcome with Different Types and Amounts of Information
133. A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients
134. A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6
135. Model-based drug development in pulmonary delivery: pharmacokinetic analysis of novel drug candidates for treatment of Pseudomonas aeruginosa lung infection
136. A Pharmacokinetic-Pharmacodynamic model built on in vitro data predicts the antibacterial effect of polymyxin B against Klebsiella pneumoniae in vivo
137. Application of pharmacokinetic-pharmacodynamic modeling in management of QT abnormalities after citalopram overdose. Reply to A. Manini
138. Reply to Dr. Mégarbane et al. regarding “Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose”
139. Human methyl parathion poisoning
140. Pharmacokinetic–pharmacodynamic modelling of QT interval prolongation following citalopram overdoses
141. Pharmacokinetic–pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model
142. Pharmacokinetic/Pharmacodynamic Modelling in Oncological Drug Development
143. Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes
144. Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs
145. From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics.
146. Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin.
147. Optimization of Piperacillin-Tazobactam Treatment in Pediatric Oncology Patients with Fever - a Prospective Study':Presented as an oral presentation at the NOPHO 36th Annual Meeting | NOBOS 12th Biannual Meeting in Vilnius, Lithuania on 1-6 June, 2018 on Sunday 03-06 at 15:45-16:00
148. Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen
149. Effects of cladribine tablets on heart rate, atrio‐ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis
150. Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.